In a report published Friday, Credit Suisse analyst Vamil Divan reiterated an Outperform rating on Bristol-Myers Squibb Co. BMY, and raised the price target from $56.00 to $60.00.
In the report, Credit Suisse noted, “Details of BMY's divestiture of its stake in its diabetes joint venture (JV) with AZN reflect strong strategic merit with better than expected economics (>$6Bn in probability-adjusted NPV due to BMY from AZN). This divestiture wisely allows BMY to focus its resources on the more attractive, profitable immuno-oncology (I-O) space and leads us to reiterate our OP rating and raise our target price to $60 (from $56).”
Bristol-Myers Squibb Co. closed on Thursday at $53.84.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in